Current therapies and new developments in NASH

Jean François Dufour; Quentin M. Anstee; Elisabetta Bugianesi; Stephen Harrison; Rohit Loomba; Valerie Paradis; Herbert Tilg; Vincent Wai Sun Wong; Shira Zelber-Sagi

doi:10.1136/gutjnl-2021-326874

Current therapies and new developments in NASH

Jean François Dufour
, Quentin M. Anstee
, Elisabetta Bugianesi
, Stephen Harrison
, Rohit Loomba
, Valerie Paradis
, Herbert Tilg
, Vincent Wai Sun Wong
, Shira Zelber-Sagi

School of Public Health

Research output: Contribution to journal › Review article › peer-review

Abstract

Non-Alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.

Original language	English
Pages (from-to)	2123-2134
Number of pages	12
Journal	Gut
Volume	71
Issue number	10
Early online date	16 Jun 2022
DOIs	https://doi.org/10.1136/gutjnl-2021-326874
State	Published - 1 Oct 2022

Bibliographical note

Publisher Copyright:
©

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1136/gutjnl-2021-326874

Cite this

@article{872ffedd06be4c09a2c6ed7c9c63b726,

title = "Current therapies and new developments in NASH",

abstract = "Non-Alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.",

author = "Dufour, \{Jean Fran{\c c}ois\} and Anstee, \{Quentin M.\} and Elisabetta Bugianesi and Stephen Harrison and Rohit Loomba and Valerie Paradis and Herbert Tilg and Wong, \{Vincent Wai Sun\} and Shira Zelber-Sagi",

note = "Publisher Copyright: {\textcopyright} ",

year = "2022",

month = oct,

day = "1",

doi = "10.1136/gutjnl-2021-326874",

language = "English",

volume = "71",

pages = "2123--2134",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "10",

}

TY - JOUR

T1 - Current therapies and new developments in NASH

AU - Dufour, Jean François

AU - Anstee, Quentin M.

AU - Bugianesi, Elisabetta

AU - Harrison, Stephen

AU - Loomba, Rohit

AU - Paradis, Valerie

AU - Tilg, Herbert

AU - Wong, Vincent Wai Sun

AU - Zelber-Sagi, Shira

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Non-Alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.

AB - Non-Alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.

UR - https://www.scopus.com/pages/publications/85132796389

U2 - 10.1136/gutjnl-2021-326874

DO - 10.1136/gutjnl-2021-326874

M3 - Review article

C2 - 35710299

AN - SCOPUS:85132796389

SN - 0017-5749

VL - 71

SP - 2123

EP - 2134

JO - Gut

JF - Gut

IS - 10

ER -

Current therapies and new developments in NASH

Abstract

Bibliographical note

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this